Cargando…
Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis
BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are novel, hypoglycemic drugs exhibiting cardiovascular protective activities. If SGLT2 inhibitors can be successfully used as antihypertensive drugs, they can be administered to patients with both hypertension and type 2 diabetes, thus d...
Autores principales: | Ren, Bangjiaxin, Chen, Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747874/ https://www.ncbi.nlm.nih.gov/pubmed/36533186 http://dx.doi.org/10.1177/20420188221142450 |
Ejemplares similares
-
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
por: Li, Hang-Long, et al.
Publicado: (2022) -
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis
por: Olagunju, Abdulbaril, et al.
Publicado: (2022) -
Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports
por: Juneja, Deven, et al.
Publicado: (2023) -
Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Lou, Yake, et al.
Publicado: (2020) -
Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
por: McKee, Alexis, et al.
Publicado: (2020)